• Arcus Biosciences Inc RCUS.N reported a quarterly adjusted loss of $1.14​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -5 cents. The mean expectation of ten analysts for the quarter was for a loss of $1.03 per share. Wall Street expected results to range from $-1.27 to -80 cents per share.

• Revenue fell 80.7% to $28.00 million from a year ago; analysts expected $36.54 million.

• Arcus Biosciences Inc's reported EPS for the quarter was a loss of $1.14​.

• The company reported a quarterly loss of $112 million.

• Arcus Biosciences Inc shares had risen by 13.9% this quarter and lost 40.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 13.7% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Arcus Biosciences Inc is $29.00

This summary was machine generated from LSEG data May 6 at 09:41 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)